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Summarv We examined the lesvels of expression of the multidrug resistance-associated protein (MRP) gene
quantified by Northern blot analy sis in comparison with those of the UDRI gene determined by reverse
transcription-polI'merase chain reaction (RT-PCR) in 104 non-small-cell lung cancer (NSCLC) specimens [59
adenocarcinoma (Ad). 40 squamous cell carcinoma (Sq). four large cell carcinoma (La) and one adeno-
squamous carcinoma (AdSq)]. Thirty-three (31.7%o) of the 104 NSCLC expressed the MRP gene at sarious
levels. The NSCLC shoWing high (+ +) lesels of MRP gene expression (19 out of 33. 57.6°o) were
predominantly squamous cell carcinomas (Ad. 5: Sq. 13: La. 1) (P<0.05). Six of the eight NSCLCs expressing
high levels of MRP mRNA and no MDRJ (.URP+ +. MDR1-) were squamous cell carcinomas. Sixty-one
of the 104 NSCLC patients receised chemotherapy with MRP-related anti-cancer drugs [vindesine (VDS) and
etoposide (VP-16)]. Twenty-three patients (37.70o) With tumour expressing high or moderate levels of MRP
showed significantly worse prognoses than those With non- or low- MRP-expressing tumours (P<0.05). These
results suggest that the level of URP gene expression is related to the histopathology and prognosis of
NSCLC.
Kevwords: multidrug resistance-associated protein: non-small-cell lung cancer: multidrug resistance gene l:
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The failure of chemotherapy is an important problem in
treating non-resectable or recurrent non-small-cell lung
cancer (NSCLC) (Williams. 1989). NSCLC uusually shows
intrinsic multidrug resistance. whereas small-cell lung cancer
(SCLC) initially responds well to various anti-cancer agents
(Bergh et al.. 1990). Advanced NSCLCs are generally treated
by therapeutic protocols using cisplatin. vinca alkaloids
(vindesine (VDS). vincristine (VCR) and etoposide (VP-16))
(Dhingra et al.. 1985: Britran et al.. 1988: Richards et al..
1991).
Several types of drug resistance to anti-cancer agents have
been characterised in human carcinoma cell lines in *itro
(Fojo et al.. 1985: Gros et al.. 1986: Giaccone et al.. 1992).
The selection of cells which are resistant to lipophilic com-
pounds (anthracyclines. vinca alkaloids. podophyllotoxins
and colchicine) results in the development of cross-resistance
or multidrug resistance to other related drugs (Chen et al..
1986. 1990: Roninson. 1991). The classical form of multidrug
resistance in human cancer is due to increased activitv of the
P-glvcoprotein (P-Gp) encoded by the human multidrug
resistance zene 1 (MDRI) (Ueda et al.. 1987). Previously. we
reported no apparent correlation between the level of VDRI
expression and clinical prognosis in NSCLC. whereas a
number of adenocarcinomas expressed high levels of MDRI
as shown by reverse transcription-polymerase chain reaction
(RT-PCR) assay (Abe et al.. 1994a).
Recently. the multidrug resistance-associated protein (MRP)
gene was cloned (Cole et al.. 1992). and its expression was
shown to be related to multidrug resistance in a non-P-Gp-
mediated multidrug-resistant small-cell lung cancer cell line.
Direct evidence for the function of the MRP gene has been
obtained in a multidrug-resistant cell line transfected with
this gene (Grant et al.. 1994). The MRP gene was also
expressed in a number of inherently drug-resistant non-small-
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cell lung cancer cell lines (Cole et al., 1992). Nevertheless, the
clinical relevance of MRP gene expression is poorly under-
stood in the multidrug resistance phenomena in NSCLC.
In this study. we evaluated levels of MfRP gene expression
in 104 NSCLC specimens by Northern blotting, and also
examined levels of MDRI expression in these 104 NSCLCs.
by RT-PCR assay. The relationships between level of MRP
gene expression and clinicopathological features (histo-
pathology. pathological TNM scores and clinical prognosis)
are discussed.
Materials and methods
Patients and tumours
One hundred and four fresh NSCLC tumour specimens and
ten specimens of adjacent normal lung tissues were obtained
with informed consent at surgical resection from previously
untreated patients. Tissues were rapidly frozen and stored at
-80'C until analyses. The tumour specimens were not con-
taminated by normal lung tissues. Total cellular RNA was
prepared from the frozen specimens by standard procedures
(Sambrook et al.. 1989).
Surgical specimens were also processed for routine his-
topathological analysis. Morphological classification was
based on Histological Typing of Lung Tumours (WHO.
1982). The specimens consisted of 59 adenocarcinomas [well
differentiated (wd). 30: moderately differentiated (md). 13:
poorly differentiated (pd). 16]. 40 squamous cell carcinomas
(wd. 17: md. 14: pd. nine). four large-cell carcinomas and one
adenosquamous cell carcinoma. The tumours were classified
histologically by two pathologists. The age distnrbutions of
the patients (67 men. 37 women) were as follows: under 40
vears old. 1. 40-49. 10. 50-59. 28. 60-69. 40. 70-79. 23.
and over 80 years old. 2. TNM scores were also evaluated for
the 98 patients whose surgical specimens were subjected to
the histopathological analysis. whereas TNM scores were not
evaluated for the other six patients who underwent non-
curative operations (UICC. 1978) (Table I).Table I Pathological TNM scores
Stage I 46 p-Ti 32 p-NO 56 p-MO 86
Stage II 9 T2 46 Ni 19 Mi 12
Stage III 31 T3 19 N2 22
Stage IV 12 T4 I N3 1
Unknown' 6
8TNM scorescould not be evaluated because ofnon-curative surgical
operation. TNM scores were classified according to the TNM
Classification (UICC, 1978).
Northern blot analysis
We examined the levels of MRP transcripts in 104 NSCLCs
by Northern blot analysis. Twenty micrograms of total RNA
from each specimen was run on agarose gels (0.8%), which
were then blotted onto nylon membranes (GeneScreen Plus,
New England Nuclear). A human MRP cDNA was prepared
by PCR amplification of the fragment corresponding to
nucleotides 240-502 from KB8-5 cells (multidrug-resistant
cell line). The primers used for amplification of the 240-502
fragment were 5'-TCTGGGACTGGAATGTCACG-3' (for-
ward primer, 240-259) and 5'-CAGGAATATGCCCCGAC-
TTC-3' (reverse primer, 484-502). The MRP cDNA frag-
ment structure was confirmed by digestion analysis with
HaeIII (99 and 164bp) (data not shown). The blots were
hybridised with a 32P-labelled MRP cDNA probe under the
conditions recommended by the manufacturer (GeneScreen
Plus, NEN). We evaluated the MRP gene-specific transcript
(6.5 kb) by autoradiography and also examined housekeeping
gene expression by stripping and rehybridisation of the blots
with a P-actin cDNA probe to control for amount of RNA
loaded in each lane. The relative expression levels of the
MRP gene were evaluated by densitometry, using the
Interactive Build Analysis System (Zeiss). The levels of MRP
gene expression were calculated by multiplying the mean
density of bands by densitometric area (Itoh et al., 1992).
Reverse transcription-polymerase chain reaction (RT-PCR)
MDR] expression was determined by RT-PCR as described
in our previous report (Abe et al., 1994a). MDRJ expression
levels are, in contrast to MRP expression, generally lower
than the limit of detection of conventional Northern blot
analysis with total RNA specimens in various tumour
materials (Abe et al., 1994b). Therefore, we used the
RT-PCR method to evaluate the MDRJ expression in the
tumour matenals in the present study. The PCR products
(MDRJ, 243 bp; P,-microglobulin, 126 bp) were detected by
hybridisation with synthetic oligonucleotide probes labelled
with 3'2P.
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Resiuts
Levels ofthe MRP gene expression
The ratio of MRP to fractin gene expression (M pa) in the
samples was calculated. The levels of MRP gene expression
were subclassified into three grades: high (+ +). M pa >0.06:
moderate (+), 0.01.M,'Pa<0.06; none or low (-). M
pa <0.01. Northern blot analyses showed an MRP gene
transcript (6.5 kb) in 33 (31.7%) of the 104 NSCLCs at
moderate to high levels (Figure 1). Nineteen (18.3%) of 104
NSCLC specimens showed high-level (+ +) expression of the
MRP gene. and 14 (13.4%) showed a moderate level (+)
(Figure 2).
Ten normal lung tissue specimens showed no apparent
expression of the MRP gene. Three tumour specimens (two
adenocarcinomas and one squamous cell carcinoma) showed
increased levels of MRP gene expression as compared with
the corresponding normal lung tissue. The other seven
tumour specimens showed no apparent increase in level of
MRP gene expression (data not shown).
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Fgre 1 Northern blot of MRP transcripts in primary speci-
mens of NSCLC. Total cellular RNA (20pg) was fractionated in
each line. Lanes 1-9, patients: lanes 1. 3-4. 8-9. adenocar-
cinoma; lanes 2. 5, 7, squamous cell carcinoma: lane 6. large-cell
carcinoma; KB3- 1, in vitro drug-sensitive cell Line; KB8-5.
MDR cell line. The bands (6.5 kb) indicate MRP-specific trans-
cript signals. Blots rehybridised with a S-actin probe are shown as
internal controls. Lanes 3 and 7 show high MRP expression
(+ +), lane 4 shows moderate MRP expression (+) and the
others show no or low MRP expression (-).
Chemotherapy protocols
The post-operative chemotherapeutic protocols were designed
according to age, histology, pathological stage and resec-
tability. No patient was treated by preoperative chemo-
therapy. Sixty-one of the 104 NSCLC patients were treated
by post-operative chemotherapy with two protocols: cisplatin
(CDDP) and VDS (n = 24) or carboplatin (CBDCA) and
VP-16 (n = 37). Patients received one or two cycles of com-
bination chemotherapy at 4 week intervals. The first group
(CDDP + VDS) received a combination of CDDP 100 mg
m 2 i.v. on day 1, and VDS 3 mgm2 i.v. on days 1 and 8.
The second group (CBDCA + VP-16) received a combination
of CBDCA 300 mg m-2 on day 1, and VP-16 100mg -2 on
days 1 to 3. The first regimen was used on stage III or IV
patients until 1991, and the second has been used on all the
patients after radical resection of the NSCLC since 1992. The
survival rate was estimated by Kaplan-Meier life tables,
which were plotted to compare survival and MRP expres-
sion, and the curves were analysed for statistical significance
of differences by the generalised Wilcoxon's test with
P<0.05 taken to indicate significance.
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Figure 2 MRP expression levels in NSCLC. Gene expression
levels are shown by the ratio of the MRP P-actin expression.
NSCLCs and normal tissues were subclassified into three grades
according to the ratio of the MRP P-actin expression: (+ +).
more than 0.06; (+), 0.01-0.06: (-), less than 0.01. wd, well
differentiated; md, moderately differentiated; pd, poorly differ-
entiated. Sq, squamous cell carcinoma; Ad, adenocarcinoma; La.
large-cell carcinoma; AdSq. adenosquamous carcinoma. The
morphological classification of NSCLC was based on His-
tological Typing of Lung Tumours (WHO. 1982). 0, samples
included in survival analysis; 0. samples not included in survival
analysis.
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MRP gene expression andhistopathology ofthe NSCLC
The 33 NSCLC specimens expressing the MRP gene con-
sisted of 15 of 59 adenocarcinomas (wd, six; md, three; pd,
six). 16 of 40 squamous cell carcinomas (wd, eight; md, six;
pd. two), and two of four large-cell carcinomas (Figure 2).
The 19 NSCLC specimens showing high-level (+ +) ex-
pression of the MRP gene were predominantly composed of
squamous cell carcinomas (n = 13, 68.4%: wd, seven; md,
four; pd, two). Five (26.3%) of these 19 NSCLCs were
adenocarcinomas (md, two; pd, three), and the remaining
one (5.3%) was a large-cell carcinoma. Fourteen NSCLC
specimens showing moderate MRP gene expression (+) also
included three squamous cell carcinomas (wd, one; md, two),
ten adenocarcinomas (wd, six; md, one; pd, three)-and one
large-cell carcinoma. The incidence of squamous cell car-
cinoma was significantly dominant in the NSCLC showing
high-level (+ +) MRP gene expression (P<0.05).
MRP gene expression and MDR1 expression in the NSCLC
We examined levels of expression of MDRJ in the 104
NSCLCs. Twenty-one (20.2%) of the 104 NSCLCs expressed
both MRP and MDRI genes. Eight (7.7%) of the 104
NSCLCs showed high-level expression of the MRP gene,
while MDR] expression was not detectable, and six (75%) of
these eight NSCLCs (MRP+ +, MDR] -) were squamous
cell carcinomas. Nine (8.7%) of the 104 NSCLCs showed
high levels of MDR] expression, and eight (88.9%) of these
nine NSCLCs (MRP-, MDRJ+ +) were adenocarcinomas.
The incidence of NSCLCs showing high levels of both MRP
and MDRJ expression (MRP+ +, MDRJ+ +) was low (two
of 104, 1.9%) (Figure 3). The incidence of squamous cell
carcinomas was dominant in the eight (MRP+ +, MDR1-)
NSCLCs, while the incidence of adenocarcinoma was
dominant in the nine (MRP-, MDR] + +) NSCLCs.
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MRP gene expression and clinicalprognosis
Sixty-one of the 104 NSCLC patients were treated with
MRP-related anti-cancer agents (VDS or VP-16) according
to the post-operative chemotherapeutic protocols described in
Materials and methods. Twenty-three tumour specimens
(37.7%) from these 61 NSCLC patients expressed high or
moderate levels of MRP. The 23 patients with NSCLCs
positive for MRP expression showed a significantly lower
survival rate than those with NSCLCs expressing no or low
levels of MRP (P<0.05, generalised Wilcoxon's test) (Figure
4). Of the 61 NSCLC patients who received MRP-related
chemotherapy. 33 were categorised as stage III or IV. Four-
teen of these 33 patients with MRP-expressing NSCLCs also
showed significantly lower survival rates than the 19 patients
with non- or low-MRP-expressing NSCLCs (P<0.05, Figure
5). Nine of 20 patients with MRP-expressing squamous
cell carcinomas who received post-operative chemotherapy
showed lower survival rates than the 11 patients with non- or
low-MRP-expressing squamous cell carcinoma (P<0.01,
Figure 6). However, the patients with MRP-expressing
adenocarcinoma did not show a significantly worse prognosis
than those whose tumour tissue was negative or showed low
levels of MRP expression (Figure 7).
In this study, we examined MRP gene expression in 104
NSCLC specimens which we subclassified into three grades
according to expression level. Thirty-three (31.7%) of the 104
tumour specimens expressed the MRP gene at vanrous levels
[(+ +), 19; (+). 14], while none of the normal lung tissue
specimens showed MRP gene expression. Squamous cell car-
cinomas were significantly dominant in the NSCLCs showing
high-level (+ +) MRP gene expression (P<0.05). Patholo-
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Fiure 5 Survival curve of the stage III and IV patients with
post-operative chemotherapy. MRP (+) patients (solid line)
showed worse prognosis than MRP (-) patients (broken line)
(generalised Wilcoxon's test, P<0.05).
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Figure 4 Prognosis of patients treated post-operatively with
CDDP + VDS or CBDCA + VP-16. The overall survival rate of
61 patients is shown on a Kaplan-Meier plot. The prognosis of
MRP (+) patients (solid line) was significantly worse than that
of the MRP (-) patients (broken line) (generalised Wilcoxon's
test, P<0.05).
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Figure 6 MRP-expressing squamous cell carcinoma patients
(solid line) receiving post-operative chemotherapy showed lower
survival rate than those with non-MRP-expressing squamous cell
carcinoma (broken line) (generalised Wilcoxon's test. P<0.01).
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Figre 7 Patients with AMRP-expressing adenocarcinoma (solid
line) showed no significantly worse prognosis than those negative
for MRP expression (broken line).
gical TNM scores were estimated for 29 of the 33 NSCLCs
positive for MRP gene expression; the relationships between
the levels of MRP gene expression and pathological TNM
scores were not significant. Thomas et al. (1994) reported
that MRP is expressed in areas of lymphocytic infiltration in
human lung cancer. Histopathological evaluation of the
NSCLC showed no apparent relationship between lym-
phocytic infiltration levels and MRP expression. Thus, we
consider that the infiltration of lymphocytes does not greatly
influence the level of MRP expression in NSCLC. We have
no data at present on the heterogeneity of MRP expression
in NSCLC at the single-cell level; such in situ hybridisation
data would be helpful in discussion of the influence of lym-
phocytic infiltration on MRP expression. We did not analyse
MRP protein in NSCLCs in this study. Immunohis-
tochemical studies with anti-MRP monoclonal antibodies
would be helpful (FHens et al., 1994), and such studies are
now in progress in our laboratory.
We also examined levels of MDR] expression in the
104 NSCLCs. The incidence of NSCLCs showing high
levels of both MRP and MDR] gene expression (MRP+ +,
MDRJ+ +) was low (two of 104, 1.9%). The incidence of
squamous cell carcinoma was dominant in the eight
(MRP+ +, MDR] -) NSCLCs, while adenocarcinomas were
dominant in the nine (MRP-, MDR] + +) NSCLCs.
Twenty-three patients with MRP-expressing NSCLCs were
treated with MRP-related anti-cancer drugs (VDS or VP-16)
and showed worse prognosis than the 38 patients with non-
MRP-expressing NSCLCs. Poor prognosis showed a sig-
nificant correlation with the level of MRP gene expression in
the NSCLC. The prognoses of the patients with MRP-
expressing squamous cell carcinoma were sigmficantly worse
than those of patients with non-MRP-expressing NSCLC.
The patients with MRP-expressing adenocarcinoma did not
show a significantly worse prognosis than those whose
tumours were negative for MRP expression. These results
suggest that MRP gene expression contributes to the multi-
drug resistance phenomenon in squamous cell carcinoma but
not in adenocarcinoma. Previously, we reported that there
was no significant correlation between expression of MDR]
and prognosis in patients with NSCLC, while a number of
adenocarcinomas expressed high levels of MDR] as shown
by RT-PCR assay (Abe et al., 1994b). The extremely low
incidence (1.9%) of NSCLC with high-level expression of
both MRP and MDR] genes also suggests that the MRP
molecule plays certain important roles in multidrug resistance
in NSCLCs, distinct from those of the P-Gp molecule. MRP
is an important molecule for the mechanism of multidrug
resistance in NSCLC. However, MRP gene expression could
not completely explain the multidrug resistance phenomenon
in NSCLC. Zaman et al. (1993) also reported that over-
expression of the MRP gene cannot account for all forms of
non-P-Gp multidrug resistance in lung cancer cell lines.
Therefore, other mechanisms probably contribute to multi-
drug resistance in NSCLC.
MRP was first described as a molecule related to multidrug
resistance in a non-P-Gp-mediated multidrug-resistant small-
cell lung cancer (Cole et al., 1992). The results of the present
study suggest the predominant clinical relevance of MRP
gene expression in the multidrug resistance phenomenon of
NSCLC. Many studies have demonstrated atypical non-P-
Gp-mediated multidrug resistance in lung cancer (Slovak et
al., 1988; Cole et al., 1989; Baas et al., 1990; Reeve et al.,
1990; Versantvoort et al., 1992; Nieuwint et al., 1992). This
study strongly supports the concept that MRP is a major
molecule involved in the atypical non-P-Gp-mediated multi-
drug resistance in NSCLC.
Abbreviatols: MRP, multidrug resistance-associated protein; AUDRL.
human multidrug resistance gene 1; P-Gp. P-glycoprotein: SCLC.
small-cell lung cancer; NSCLC. non-small-cell lung cancer
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